Peginterferon lambda for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomised trial

Kandel et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2025.08.003, ILIAD Cohort B, NCT04354259, Aug 2025
Late treatmentDouble-blind RCT · NCT04354259 · 94 patients · multinational
Peg.. Lambda for COVID-19
Outcome
Improvement
Relative Risk · 95% CI
00.511.52+
← Peginterferon
Lambda reduces risk
Increased risk →
Worse 7-point scale results with treatment
Not statistically significant · p = 0.49
RCT 97 hospitalized COVID-19 patients showing no significant benefit with peginterferon lambda.
OutcomeImprovementEffect · pTreatmentControl
risk of 7-point scale 31.6% higher · OR 1.32 · p = 0.49 31.6% higherOR 1.32p = 0.49 48 46 treatment 48, control 46inverted to make OR<1 favor treatmentRR approximated with ORday 14

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Kandel et al., 14 Aug 2025, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 21 authors, trial NCT04354259 (history) (ILIAD Cohort B).
Late treatment
is less effective